Rabbit Polyclonal GFRA3 Antibody

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue lysate, Primary antibody: P03987(GFRA3 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P03987(GFRA3 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P03987(GFRA3 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The GFRA3 antibody targets the GDNF family receptor alpha-3 (GFRα3), a cell-surface glycoprotein that serves as a co-receptor for the neurotrophic factor artemin (ARTN). GFRα3 is a member of the GDNF receptor family, which includes four alpha receptors (GFRα1-4) that bind distinct ligands (GDNF, neurturin, artemin, and persephin) and activate RET tyrosine kinase signaling. GFRα3 is primarily expressed in peripheral sensory and sympathetic neurons, where it plays a critical role in neuronal development, survival, and pain signaling. It is also implicated in cancer progression, as aberrant ARTN-GFRα3-RET signaling has been linked to tumor invasiveness and metastasis in certain malignancies.

Antibodies against GFRα3 are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques such as immunohistochemistry, Western blotting, and flow cytometry to investigate GFRα3 distribution in tissues, its interaction with ARTN, and its role in diseases like neuropathic pain, neurodevelopmental disorders, and cancers (e.g., breast, pancreatic). Commercial GFRA3 antibodies are typically raised in hosts like rabbits or mice, with validation data confirming specificity through knockout controls or siRNA knockdown. Researchers utilize these antibodies to explore therapeutic strategies targeting the ARTN-GFRα3 axis, particularly in pain management and oncology.